Under construction – not a live service
Sign in
Not yet taking people in ChinaNo phase

Robotic versus expert manual prostate biopsy in men with obesity

Compares robot-assisted and manual prostate biopsy in men with obesity.

Plain-language title generated from the registry record
Registry title: A Multicenter, Randomized Controlled Superiority Trial Comparing Robotic-Assisted Versus Expert Cognitive Fusion Prostate Biopsy in Obese Men

Key facts

Where
Shanghai, ChinaSee the site

Where in China

  • Shanghai East HospitalShanghai, ChinaNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Shanghai East Hospital
Trial code
NCT07600216
Record updated
30 October 2026
Original description
The trial aims to find out if using a robotic system to help perform prostate biopsies is better than having a highly experienced doctor perform the biopsy by hand in men with a high Body Mass Index (BMI).Read full original descriptionShow less

A Multicenter, Randomized Controlled Superiority Trial Comparing Robotic-Assisted Versus Expert Cognitive Fusion Prostate Biopsy in Obese Men

The trial aims to find out if using a robotic system to help perform prostate biopsies is better than having a highly experienced doctor perform the biopsy by hand in men with a high Body Mass Index (BMI).

While MRI-guided prostate biopsies are highly effective, carrying them out in men with obesity can be physically challenging for doctors. Extra pelvic tissue increases the depth the biopsy needle must travel and makes it difficult to manually hold the ultrasound probe perfectly steady. This physical difficulty might cause doctors to miss some aggressive prostate cancers.

This study tests whether a robotic arm-which completely locks the biopsy needle on target and eliminates human hand tremors-can improve cancer detection. The study will enroll up to 570 men with high BMI who have suspicious areas on their prostate MRI. Participants will be randomly assigned to receive either a robotic-assisted biopsy or a standard manual biopsy performed by an expert urologist.

To ensure the results are completely unbiased, participants will not know which method is being used on them. They will be placed behind a surgical drape and wear noise-canceling headphones playing music during the procedure to block out the sounds of the robotic motors. The main goal is to see if the robotic method safely and significantly increases the detection rate of clinically significant prostate cancer in this specific group of patients.

Inclusion: Age ≥ 40 years; Serum PSA levels between 4 and 20 ng/ml and/or abnormal digital rectal examination (DRE); High Body Mass Index (BMI): defined as ≥ 28 kg/m ² for Asian cohorts and ≥ 30 kg/m ² for Non-Asian cohorts; MRI-Positive: Presence of at least one suspicious lesion (PI-RADS score ≥ 3) on mpMRI; Fitness for transperineal biopsy under local anaesthesia or conscious sedation.

Exclusion: Prior treatment for prostate cancer; History of major anorectal surgery preventing safe transperineal probe insertion; Contraindications to MRI; Negative screening MRI (PI-RADS 1-2).

ClinicalTrials.gov NCT07600216